Shares of ProKidney Corp. (NASDAQ:PROK – Get Free Report) have been given an average rating of “Moderate Buy” by the six brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $15.33.
Separately, BTIG Research began coverage on shares of ProKidney in a report on Monday, July 24th. They set a “buy” rating and a $16.00 price objective on the stock.
ProKidney Trading Up 0.4 %
ProKidney (NASDAQ:PROK – Get Free Report) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.27. On average, equities research analysts expect that ProKidney will post -1.2 earnings per share for the current year.
Hedge Funds Weigh In On ProKidney
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in ProKidney during the second quarter worth about $31,000. Salem Investment Counselors Inc. raised its position in ProKidney by 547.9% during the second quarter. Salem Investment Counselors Inc. now owns 3,000 shares of the company’s stock worth $34,000 after acquiring an additional 2,537 shares during the last quarter. Metropolitan Life Insurance Co NY acquired a new position in ProKidney during the second quarter worth about $38,000. Tower Research Capital LLC TRC raised its position in ProKidney by 98.5% during the first quarter. Tower Research Capital LLC TRC now owns 4,456 shares of the company’s stock worth $50,000 after acquiring an additional 2,211 shares during the last quarter. Finally, Ameritas Investment Partners Inc. acquired a new position in ProKidney during the second quarter worth about $57,000. Institutional investors and hedge funds own 16.94% of the company’s stock.
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
- Five stocks we like better than ProKidney
- Video Game Stocks: How to Invest in Gaming
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- With Risk Tolerance, One Size Does Not Fit All
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How to Invest in Communication Stocks
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.